Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine

Clin Infect Dis. 2014 Sep 15;59(6):862-5. doi: 10.1093/cid/ciu409. Epub 2014 May 30.

Abstract

Current guidelines recommend a combined schedule of a 13-valent pneumococcal conjugate vaccine (PCV13) and PPSV23 (23-valent polysaccharide vaccine) for asplenic individuals. We show that PCV13 induces a T-dependent immune response in asplenic individuals with β-thalassemia, but previous PPSV23s affect the memory B-cell response in a dose- and time-dependent manner. Clinical Trials Registration. NCT01846923.

Keywords: immunological hyporesponsiveness; immunological memory; memory B cells; pneumococcal vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Bacterial / immunology
  • B-Lymphocytes / immunology*
  • Epitopes, B-Lymphocyte / immunology*
  • Female
  • Humans
  • Immunoglobulin G / immunology
  • Immunoglobulin M / immunology
  • Immunologic Memory
  • Male
  • Middle Aged
  • Pneumococcal Infections / microbiology*
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage
  • Pneumococcal Vaccines / immunology*
  • Serogroup
  • Splenectomy / adverse effects
  • Streptococcus pneumoniae / classification
  • Streptococcus pneumoniae / immunology*
  • Vaccination
  • Young Adult
  • beta-Thalassemia / complications
  • beta-Thalassemia / immunology*
  • beta-Thalassemia / surgery

Substances

  • 13-valent pneumococcal vaccine
  • 23-valent pneumococcal capsular polysaccharide vaccine
  • Antibodies, Bacterial
  • Epitopes, B-Lymphocyte
  • Immunoglobulin G
  • Immunoglobulin M
  • Pneumococcal Vaccines

Associated data

  • ClinicalTrials.gov/NCT01846923